Cargando…
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
Patients with FLT3-mutated AML have a high relapse rate and suboptimal outcomes. Many have co-mutations suitable for measurable residual disease (MRD) monitoring by RT-qPCR and those destined to relapse can be identified by high or rising levels of MRD, called molecular failure. This provides a win...
Autores principales: | Othman, Jad, Potter, Nicola, Mokretar, Katya, Taussig, David, Khan, Anjum, Krishnamurthy, Pramila, Latif, Anne-Louise, Cahalin, Paul, Aries, James, Amer, Mariam, Belsham, Edward, Conneally, Eibhlin, Craddock, Charles, Culligan, Dominic, Dennis, Mike, Duncan, Caroline, Freeman, Sylvie D., Furness, Caroline, Gilkes, Amanda, Gkreka, Paraskevi, Hodgson, Katherine, Ingram, Wendy, Jain, Manish, King, Andrew, Knapper, Steven, Kottaridis, Panagiotis, McMullin, Mary Frances, Mohite, Unmesh, Ngu, Loretta, O’Nions, Jenny, Patrick, Katharine, Rider, Tom, Roberts, Wing, Severinsen, Marianne Tang, Storrar, Neill, Taylor, Tom, Russell, Nigel H., Dillon, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539160/ https://www.ncbi.nlm.nih.gov/pubmed/37558736 http://dx.doi.org/10.1038/s41375-023-01994-x |
Ejemplares similares
-
S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL
por: Russell, Nigel, et al.
Publicado: (2023) -
getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019) -
Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome
por: Loo, Sun, et al.
Publicado: (2022) -
P484: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. UPDATED TOXICITY AND INTERIM SURVIVAL ANALYSIS FROM THE NCRI AML19V2 “MIDOTARG” PILOT TRIAL
por: Russell, Nigel, et al.
Publicado: (2023) -
Further Activation of FLT3 Mutants by FLT3 Ligand
por: Zheng, Rui, et al.
Publicado: (2011)